Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

被引:6
作者
Poulet, Sophie [1 ]
Dai, Meiou [1 ]
Wang, Ni [1 ]
Yan, Gang [1 ]
Boudreault, Julien [1 ]
Daliah, Girija [1 ]
Guillevin, Alan [1 ]
Nguyen, Huong [1 ]
Galal, Soaad [1 ]
Ali, Suhad [1 ]
Lebrun, Jean-Jacques [1 ]
机构
[1] McGill Univ, Dept Med, Hlth Ctr, Canc Res Program, Montreal, PQ, Canada
关键词
PROMOTES RB DEGRADATION; UBIQUITIN LIGASE; CDK INHIBITORS; CELL-LINES; ESTROGEN; INVOLUTION; EXPRESSION; GENES; MODEL;
D O I
10.1186/s12943-024-02029-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple negative breast cancer (TNBC) remains exceptionally challenging to treat. While CDK4/6 inhibitors have revolutionized HR + breast cancer therapy, there is limited understanding of their efficacy in TNBC and meaningful predictors of response and resistance to these drugs remain scarce. We conducted an in vivo genome-wide CRISPR screen using palbociclib as a selection pressure in TNBC. Hits were prioritized using microarray data from a large panel of breast cancer cell lines to identify top palbociclib sensitizers. Our study defines TGF beta 3 as an actionable determinant of palbociclib sensitivity that potentiates its anti-tumor effects. Mechanistically, we show that chronic palbociclib exposure depletes p21 levels, contributing to acquired resistance, and that TGF beta 3 treatment can overcome this. This study defines TGF beta 3 as an actionable biomarker that can be used to improve patient stratification for palbociclib treatment and exploits the synergistic interaction between CDK4/6 and TGF beta 3 to propose a new combinatorial treatment for TNBC.
引用
收藏
页数:21
相关论文
共 69 条
[1]   Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma [J].
AbuHammad, Shatha ;
Cullinane, Carleen ;
Martin, Claire ;
Bacolas, Zoe ;
Ward, Teresa ;
Chen, Huiqin ;
Slater, Alison ;
Ardley, Kerry ;
Kirby, Laura ;
Chan, Keefe T. ;
Brajanovski, Natalie ;
Smith, Lorey K. ;
Rao, Aparna D. ;
Lelliott, Emily J. ;
Kleinschmidt, Margarete ;
Vergara, Ismael A. ;
Papenfuss, Anthony T. ;
Lau, Peter ;
Ghosh, Prerana ;
Haupt, Sue ;
Haupt, Ygal ;
Sanij, Elaine ;
Poortinga, Gretchen ;
Pearson, Richard B. ;
Falk, Hendrik ;
Curtis, David J. ;
Stupple, Paul ;
Devlin, Mark ;
Street, Ian ;
Davies, Michael A. ;
McArthur, Grant A. ;
Sheppard, Karen E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (36) :17990-18000
[2]   INVOLUTION OF MOUSE MAMMARY-GLANDS IN WHOLE-ORGAN CULTURE - A MODEL FOR STUDYING PROGRAMMED CELL-DEATH [J].
ATWOOD, CS ;
IKEDA, M ;
VONDERHAAR, BK .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 207 (02) :860-867
[3]   A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity [J].
Barghout, Samir H. ;
Aman, Ahmed ;
Nouri, Kazem ;
Blatman, Zachary ;
Arevalo, Karen ;
Thomas, Geethu E. ;
MacLean, Neil ;
Hurren, Rose ;
Ketela, Troy ;
Saini, Mehakpreet ;
Abohawya, Moustafa ;
Kiyota, Taira ;
Al-Awar, Rima ;
Schimmer, Aaron D. .
JCI INSIGHT, 2021, 6 (05)
[4]   TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer [J].
Bhola, Neil E. ;
Balko, Justin M. ;
Dugger, Teresa C. ;
Kuba, Maria Gabriela ;
Sanchez, Violeta ;
Sanders, Melinda ;
Stanford, Jamie ;
Cook, Rebecca S. ;
Arteaga, Carlos L. .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (03) :1348-1358
[5]   BREAST TUMOR-CELL LINES FROM PLEURAL EFFUSIONS [J].
CAILLEAU, R ;
YOUNG, R ;
OLIVE, M ;
REEVES, WJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 53 (03) :661-674
[6]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404
[7]   MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance [J].
Cornell, Liam ;
Wander, Seth A. ;
Visal, Tanvi ;
Wagle, Nikhil ;
Shapiro, Geoffrey I. .
CELL REPORTS, 2019, 26 (10) :2667-+
[8]   Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].
Cristofanilli, Massimo ;
Turner, Nicholas C. ;
Bondarenko, Igor ;
Ro, Jungsil ;
Im, Seock-Ah ;
Masuda, Norikazu ;
Colleoni, Marco ;
DeMichele, Angela ;
Loi, Sherene ;
Verma, Sunil ;
Iwata, Hiroji ;
Harbeck, Nadia ;
Zhang, Ke ;
Theall, Kathy Puyana ;
Jiang, Yuqiu ;
Bartlett, Cynthia Huang ;
Koehler, Maria ;
Slamon, Dennis .
LANCET ONCOLOGY, 2016, 17 (04) :425-439
[9]   The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups [J].
Curtis, Christina ;
Shah, Sohrab P. ;
Chin, Suet-Feung ;
Turashvili, Gulisa ;
Rueda, Oscar M. ;
Dunning, Mark J. ;
Speed, Doug ;
Lynch, Andy G. ;
Samarajiwa, Shamith ;
Yuan, Yinyin ;
Graef, Stefan ;
Ha, Gavin ;
Haffari, Gholamreza ;
Bashashati, Ali ;
Russell, Roslin ;
McKinney, Steven ;
Langerod, Anita ;
Green, Andrew ;
Provenzano, Elena ;
Wishart, Gordon ;
Pinder, Sarah ;
Watson, Peter ;
Markowetz, Florian ;
Murphy, Leigh ;
Ellis, Ian ;
Purushotham, Arnie ;
Borresen-Dale, Anne-Lise ;
Brenton, James D. ;
Tavare, Simon ;
Caldas, Carlos ;
Aparicio, Samuel .
NATURE, 2012, 486 (7403) :346-352
[10]   In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy [J].
Dai, Meiou ;
Yan, Gang ;
Wang, Ni ;
Daliah, Girija ;
Edick, Ashlin M. ;
Poulet, Sophie ;
Boudreault, Julien ;
Ali, Suhad ;
Burgos, Sergio A. ;
Lebrun, Jean-Jacques .
NATURE COMMUNICATIONS, 2021, 12 (01)